FOLH1 and prostate carcinoma: Positron-emission-tomography (PET) using [68Ga]Gallium-labeled ligands of the prostate-specific membrane antigen (PSMA) localizes recurrent prostate cancer with high accuracy and significant impact on management as demonstrated in several retrospective reports and a recent prospective study [1–4].